Question 1

How does EquitAI evaluate Harvard Bioscience, Inc.'s (HBIO) valuation and Stock DNA?

Accepted Answer

Harvard Bioscience, Inc. (HBIO) trades at $8.90 with an EquitAI Valuation DNA score of 4/10 and Quality score of 1/10. These scores evaluate balance sheet leverage, free cash flow generation, and fundamental multiples against historical benchmarks.

Question 2

What sector and industry does Harvard Bioscience, Inc. (HBIO) operate in?

Accepted Answer

Harvard Bioscience, Inc. (HBIO) is classified under the Healthcare sector within the Medical - Instruments & Supplies industry. EquitAI benchmarks its fundamental valuation and financial DNA metrics against both direct Medical - Instruments & Supplies peers and broader Healthcare market benchmarks.

Question 3

What is Wall Street's price target and consensus rating for Harvard Bioscience, Inc. (HBIO)?

Accepted Answer

Wall Street analysts have a consensus 12-month price target of $38.0 for Harvard Bioscience, Inc. (HBIO), representing an implied 327.0% upside from its current trading level of $8.90 with an average rating of Buy based on 1 analyst rating. Because this forecast is provided by a single analyst, it represents limited coverage and may reflect historical or isolated expectations rather than a broad consensus. EquitAI benchmarks analyst consensus projections against intrinsic Financial DNA valuation pillars.

Question 4

Does HBIO pay dividends or capital distributions?

Accepted Answer

Harvard Bioscience, Inc. does not currently pay a regular dividend yield, prioritizing capital reinvestment into operations, product development, and balance sheet strength.

Question 5

Who are Harvard Bioscience, Inc.'s (HBIO) primary market competitors and peers?

Accepted Answer

Key market peers and semantic competitors include LAB, MXCT, HAE, BRKR. EquitAI maps peer relationships through semantic business models, institutional capital flow correlation, and market capitalization weighting.

Question 6

How should investors interpret EquitAI's HBIO analysis?

Accepted Answer

EquitAI provides quantitative financial research, algorithmic DNA scores, and SEC contextual analytics for informational and research purposes. It does not constitute personalized financial advice or broker-dealer investment recommendations.

HBIO - Harvard Bioscience, Inc. Stock Analysis & Valuation

Harvard Bioscience, Inc.

FIT ANALYSIS